Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838850 | 0.89 | SCD5 (0.44) | SCD5USP30GPR119CKS1BSKP1 | |
| SCHEMBL2429818 | 0.85 | TACR1 (0.45) | SCD5USP30GPR119TACR1 | |
| SCHEMBL2424711 | 0.84 | YAP1 (0.46) | SCD5USP30GPR119ATMTACR1 | |
| SCHEMBL20395989 | 0.84 | PDK2 (0.41) | GPR119TSHRALOX15ATMTACR1 | |
| SCHEMBL30835857 | 0.80 | MAPT (0.43) | SCD5USP30GPR119TACR1 | |
| SCHEMBL20412572 | 0.80 | GRM5 (0.45) | SCD5GPR119TSHRALOX15ATM | |
| SCHEMBL25528784 | 0.80 | USP2 (0.45) | GPR119TSHRALOX15ATMCHRM2 | |
| SCHEMBL25541363 | 0.80 | USP2 (0.45) | GPR119TSHRALOX15ATMCHRM2 | |
| SCHEMBL20396116 | 0.79 | IDH1 (0.52) | USP30GPR119TACR1 | |
| SCHEMBL20395937 | 0.78 | JAK2 (0.42) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | SCD5 2596/4885USP30 4334/4885GPR119 1545/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | SCD5 2596/4885USP30 4334/4885GPR119 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.